Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03849651CT.gov TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Aggressive NK-Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd45ra-depleted dli (this asset) | St. Jude Children's Research Hospital | P2 | CCC · 53 |
| Cyclophosphamide | The Affiliated Hospital of Xuzhou Medical University | P2 | B |
| Melphalan | St. Jude Children's Research Hospital | P2 | CCC |
| Blinatumomab | St. Jude Children's Research Hospital | P2 | CCC |
| Anti-Cd56 Car T | The Affiliated Hospital of Xuzhou Medical University | P2 | CCC |
| Mesna | St. Jude Children's Research Hospital | P2 | CCC |
| Fludarabine | The Affiliated Hospital of Xuzhou Medical University | P2 | CCC |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | St. Jude Children's Research Hospital | P2 | CCC |
| Thiotepa | St. Jude Children's Research Hospital | P2 | CCC |
+12 more in the Aggressive NK-Cell Leukemia cohort
Other indications for cd45ra-depleted dli
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P2 | CCC · 53 |
| Myelodysplastic Syndrome | — | P2 | CCC · 53 |
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd45ra-depleted dli in Aggressive NK-Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd45ra-depleted-dli-aggressive-nk-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →